Last $0.03 USD
Change Today +0.0015 / 5.26%
Volume 2.7M
BHRT On Other Exchanges
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $0.08
52 Week Low
12/12/13 - $0.0063
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy that has completed Phase II-a study and designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients. The company also develops MyoCell SDF-1, an autologous cell therapy treatment for severe chronic damage to the heart and cells modified to express angiogenic factors; LipiCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia; and MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

3 Employees
Last Reported Date: 03/25/14
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $766.7K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $284.2K
Compensation as of Fiscal Year 2013.

bioheart inc (BHRT) Key Developments

Bioheart, Inc. Announces Clinical Study for Degenerative Disc Disease

Bioheart, Inc. announced that it will enroll patients in a new study for degenerative disc disease (DDD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell(TM) in patients with DDD. The company has initiated this new study for DDD which will include a randomized control arm. The study has been reviewed and approved by the Institutional Review Board (IRB) of the International Cellular Medicine Society (ICMS). The ICMS IRB is committed to providing peer review of proposed studies of cell-based medical therapies based upon appropriate clinical translation, patient care and safety.

Bioheart, Inc. Enters into a Joint Venture with Magnum Cell Therapies

Bioheart, Inc. announced that it has entered into a joint venture with Magnum Cell Therapies. Magnum Cell Therapies' mission is to provide the latest regenerative medicine therapies to patients suffering from degenerative diseases. Magnum's facilities include a state of the art clinic and laboratory located in Honduras. Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to Magnum. Bioheart and Magnum will work closely with the Honduran Ministry of Health to make Bioheart protocols part of the standard of care for patients in Honduras and neighboring countries. Bioheart will assume 10% ownership of Magnum Cell Therapies. Magnum will offer these therapies to the more than 8 million people living in Honduras as well as being a premier site for medical tourism.

Bioheart, Inc. Announces Positive 6 Month Data From Angel Phase I Trial

Bioheart, Inc. released 6 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). The six month data has far exceeded its expectations. At the 6 month time point, patients are demonstrating an average improvement in exercise capacity or a six minute walk test of approximately 68 meters as compared to an average improvement of 47 meters at 3 months. 8% of the patients showed an improvement in their exercise capacity from 3 months to 6 months post stem cell injection.Another end point in the study is ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3% points in ejection fraction. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10% points.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.03 USD +0.0015

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $2.73 USD +0.01
Cytori Therapeutics Inc $2.35 USD +0.10
International Stem Cell Corp $0.16 USD +0.0003
Osiris Therapeutics Inc $12.80 USD +0.11
StemCells Inc $1.23 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 105.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 65.1x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at